ArticleJAMA cardiology2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value.
Daniel B Mark et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papertrialcites it